StreetAlpha.app
Home › Stocks › HBIO

Harvard Bioscience Inc (HBIO)

$8.66
▼ −0.23%
LAST CLOSE · NOV 20

Harvard Bioscience makes laboratory instruments and software used in life science research and preclinical drug testing. It last closed at $8.66 on Nov 20, down 0.23% on the day. The next earnings report for HBIO is expected around Tue, Feb 9, 2027. For the quarter ended Sep 2026, HBIO reported EPS of -$0.58 on revenue of $22.2M, with revenue up 7.8% from a year ago. Over its last 8 reports the stock moved an average of 8.9% the session after earnings. Over the last 12 months HBIO insiders bought $202K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is HBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold HBIO.

Key Stats

Last 12 months
Results
Revenue
$89.4M
+2.3% vs a year ago
Net income
−$11.8M
−13.2% margin
Free cash flow
−$3.2M
−3.5% margin
Gross margin
57.4%
$51.4M gross profit
Valuation
Market cap
$39.6M
4.6M shares
P/E
–
Price to sales
0.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$4.9M
At Sep 30
Debt
$37.2M
At Sep 30
Shareholder equity
$5.1M
Shares outstanding
4.6M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $118.9M$118.9MFY2021FY2022: $113.3M$113.3MFY2022FY2023: $112.3M$112.3MFY2023FY2024: $94.1M$94.1MFY2024FY2025: $86.5M$86.5MFY2025

From HBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Feb 9
Estimated date · Time not announced
Reported EPS
-$0.58
Quarter ended Sep 2026
Year ago EPS
-$0.28
Same quarter last year
Revenue
$22.2M
+7.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.01Dec '24Mar 2025: -$11.42Mar '25Jun 2025: -$0.52Jun '25Sep 2025: -$0.28Sep '25Dec 2025: $10.87Dec '25Mar 2026: -$0.77Mar '26Jun 2026: -$0.64Jun '26Sep 2026: -$0.58Sep '26Latest -$0.58
Revenue by quarter
Dec 2024: $24.6MDec '24Mar 2025: $21.8MMar '25Jun 2025: $20.4MJun '25Sep 2025: $20.6MSep '25Dec 2025: $23.7MDec '25Mar 2026: $20.8MMar '26Jun 2026: $22.7MJun '26Sep 2026: $22.2MSep '26Latest $22.2M
How HBIO moved after its last 8 reports
Average move the session after a report ±8.9%
Nov 10, 2026Time not announced+1.9%
Aug 11, 2026Time not announced−4.1%
May 12, 2026Time not announced−20.9%
Mar 12, 2026Time not announced−2.6%
Feb 10, 2026Time not announced+13.4%
Nov 6, 2025Time not announced−7.3%
Aug 11, 2025Time not announced−9.3%
May 12, 2025Time not announced+11.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on HBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on HBIO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on HBIO

Technical Analysis

HBIO · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 23% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot S1 at $8.46, and the nearest resistance the Pivot at $8.73.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 5.9%/day
Key levels
$10.2052 week high+17.8%
$8.93Pivot R1+3.1%
$8.8220 day average+1.8%
$8.80Swing high (Oct 5)+1.6%
$8.73Pivot+0.8%
$8.66Last close
$8.46Pivot S1−2.3%
$8.4350 day average−2.7%
$8.11Swing low (Nov 6)−6.4%
$7.60100 day average−12.2%
$6.69200 day average−22.7%
$4.0052 week low−53.8%
Indicators
RSI (14)48.90Middle of its rangeNeutral
MACD0.16Below its signal lineBearish
Stochastic32.1Middle of its rangeNeutral
ADX (14)28.6Trending up
Williams %R-73.7Oversold below −80, overbought above −20Neutral
CCI (20)-25.9Oversold below −100, overbought above 100Neutral
Rate of change+3.6%Change over 10 sessionsBullish
ATR (14)$0.51Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for HBIO

What happened before

See how HBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow HBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How HBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for HBIOHow many large options trades hit HBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

HBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼8 buying vs 17 selling
  • ▲Held by funds +2.0 pts
  • ▼Funds holding -4
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3337−10.8%
In funds' top 1010–
Held by funds38.7%36.7%+2.0 pts
New / increased2 / 64 / 5−11.1%
Reduced / sold out11 / 615 / 20.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

HBIO Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$202K4 buys · 4 insiders
Sold$00 sales · 0 insiders
Cluster buy: 4 insiders bought $202K between Mar 16 and Mar 17.
2026-03 bought $202KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 17William SniderDirectorBuy21,000$4.93$104K
Mar 17Stephen J DenelskyDirectorBuy10,000$4.87$49K
Mar 16Mark T FrostCFOBuy5,000$5.00$25K
Mar 16John D DukeCEOBuy5,000$5.01$25K
Every insider buy and sale for HBIO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See HBIO insider trades →

From SEC Form 4 filings by HBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HBIO is in one of them and how their past HBIO trades turned out.

HBIO in the AI portfolios
Loading…

HBIO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HBIO in an article yet. Here's the latest on the wider market.

HBIO in the news

About Harvard Bioscience

Harvard Bioscience makes laboratory instruments, consumables, software and services used in life science research, drug discovery and preclinical testing. Its products include electroporation systems, syringe pumps, spectrophotometers, electrophysiology equipment and telemetry systems that collect data from research animals. Customers include pharmaceutical and biotechnology companies, contract research organizations, universities and government laboratories. The company is based in Holliston, Massachusetts, and sells in the United States, Europe and China.

Headquarters
Holliston, MA
Founded
1901